Based on our comparator data, it is possible that the peptidic MC4R agonists capable of inducing MC4R internalization may be considered suitable drug candidates for therapeutic intervention for the treatment of obesity. Here, MC4R is linked to obesity due to melanocortin 4 receptor deficiency.